Benutzer: Gast  Login
Titel:

RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients.

Dokumenttyp:
Journal Article; Research Support, Non-U.S. Gov't; Journal Article
Autor(en):
Fahrig, R; Quietzsch, D; Heinrich, JC; Heinemann, V; Boeck, S; Schmid, RM; Praha, C; Liebert, A; Sonntag, D; Krupitza, G; Hänel, M
Abstract:
RP101 [(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)], which supports apoptosis and prevents the acquisition of chemoresistance, was tested in cultured human pancreatic tumor cells. RP101 downregulated uridine phosphorylase, a marker of poor prognosis, and APEX1, which is involved in DNA repair, and repressed Stat3 and its target vascular endothelial growth factor. Furthermore, RP101 activated antitumor immunity as demonstrated by enhanced cytolytic activity of NK-92 natural killer cells. This was...     »
Zeitschriftentitel:
Anticancer Drugs
Jahr:
2006
Band / Volume:
17
Heft / Issue:
9
Seitenangaben Beitrag:
1045-56
Sprache:
eng
Volltext / DOI:
doi:10.1097/01.cad.0000231472.92406.d2
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/17001178
Print-ISSN:
0959-4973
TUM Einrichtung:
II. Medizinische Klinik und Poliklinik (Gastroenterologie)
 BibTeX